AZN's strength was still its array of valuable product for a range of healthcare issues, and without any negative factor such as patent expiry in the near future, it didn't warrant the dip in price seen near the end of last year.
Now with the strength of its previous quarter earnings, and fueled by a growth outlook with this piece of news: "AstraZeneca (AZN.L), opens new tab will buy longtime partner FibroGen's (FGEN.O), opens new tab China unit for about $160 million to gain rights to its anemia drug in the country, further boosting its presence in the world's second-biggest economy.", it's a good time for me to cash in on my gains and rotate to other tickers.
I might miss out on AZN rising to $80, but i'm content with my gains and don't want to risk keeping my capital locked in for too long.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- Valerie Archibald·02-28Will be at $100 by end of this year. The market makers will take the reins off this beast very soon …1Report
- Venus Reade·02-28AZN is definitely a great awesome stock but moves too slow for me anymore.1Report
- AdelaideFox·02-26Smart decision1Report
- OwenBess·02-26Smart move1Report